Skip to content

External Pharyngeal Exerciser for Dysphagia

Impact of External Pharyngeal Exerciser on Dysphagia in Patients With Pharyngeal Weakness

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05267314
Enrollment
30
Registered
2022-03-04
Start date
2021-12-07
Completion date
2022-12-06
Last updated
2022-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia, Oral Pharyngeal Dysphagia, Pharyngeal Dysphagia

Brief summary

Pharyngeal muscle weakness and dysphagia is common in individuals post-stroke or with Parkinson's disease and in individuals with head/neck cancer who have undergone surgery and/or radiation therapy. Therapeutic options for these patients are limited. This pilot study is intended to assess the feasibility, safety, and efficacy of the External Pharyngeal Exerciser (EPE) on patients with pharyngeal dysphagia receiving swallow therapy. Feasibility will be assessed by patient acceptance and practice records. Safety will be compared between groups to test whether there is an increased risk of the EPE versus standard therapy.

Detailed description

Pharyngeal dysphagia is incredibly common in individuals who suffer from neurological disorders such as stroke or Parkinson's disease and in individuals with head/neck cancer who have undergone surgery and/or radiation therapy. The pharyngeal muscles in these patients are weak. Other than standard patient-driven swallow therapy, the therapeutic options for these patients are limited. Response to standard patient-drive therapy is variable and dependent on a variety of factors including the muscles most affected by the underlying disorder and patient motivation. This pilot study is intended to assess the feasibility, safety, and efficacy of the External Pharyngeal Exerciser (EPE) on patients with pharyngeal dysphagia receiving swallow therapy. Feasibility will be assessed by patient acceptance and practice records. Safety will be compared between groups to test whether there is an increased risk of the EPE versus standard therapy.

Interventions

DEVICEpharyngeal exerciser + standard therapy

Use of Pharyngeal exerciser

Sponsors

University of Southern California
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pharyngeal dysphagia diagnosed with validated questionnaire and modified barium swallow. Participants must be at least 18 years of age or older. * Pharyngeal dysphagia secondary to central neurological disorder such as Parkinson's disease or stroke * Pharyngeal dysphagia head/neck cancer secondary to surgery/radiation * Pharyngeal dysphagia secondary to elderly age \> 65

Exclusion criteria

* Carotid artery bruit or carotid vascular disorders * Muscle diseases like muscular dystrophies, myopathies * Neuro-muscular junction disorders myasthenia gravis, Eaton-Lambert disorders * Current esophageal symptoms like heartburn, dysphagia, chest pain or regurgitation * Autonomic dysfunction * Pregnancy or lactation * Advanced uncontrolled medical disorders (COPD, congestive heart failure, cirrhosis, cancer, chronic renal failure, etc) * Medically unstable

Design outcomes

Primary

MeasureTime frameDescription
Determine the number of adverse events associated with EPE1 yearThe aim is to determine whether there are any risks associated with the use of the EPE. There are no known risks to placing external pressure to the larynx. However, there is the possibility that the participant may experience discomfort such as rash or may not be able to tolerate the minimal pressure associated with the exerciser. The participant will be evaluated every two weeks by the study physician and reports of adverse events will be recorded. If the participant experiences difficulty in tolerating the minimal pressure, the study will be stopped.
Determine efficacy as assessed by validated pharyngeal dysphagia questionnaire EAT-101 yearSubjective evaluation of participant response to an External Pharyngeal Exerciser with a validated pharyngeal dysphagia questionnaire (EAT-10) administered as standard of care before and after therapy (scores 1-10, with higher scores mean worse outcome).
Determine efficacy: effect of EPE on swallowing via effects on pyriform sinus and vallecular residue height and width1 yearTo objectively define pharyngeal response to External Pharyngeal Exerciser with Modified Barium swallow before and after therapy: To determine if application of pharyngeal exerciser changes swallowing as evidenced by reduction in height and width of pyriform sinus and vallecular residue using fluoroscopy study.
Determine efficacy: effect of EPE on swallowing via effects on routinely measured markers of deglutition (penetration-aspiration scale, larynx and hyoid anterior/superior excursion; UES diameter, and pharyngeal transit time)1 yearTo objectively define pharyngeal response to External Pharyngeal Exerciser with Modified Barium swallow before and after therapy: To determine if application of pharyngeal exerciser changes deglutition as noticed by 1) change in aspiration and penetration measured by Rosenbek's penetration-aspiration scale; 2) change in anterior and superior excursion of larynx and hyoid; 3) change in AP and Lateral diameter of UES; 4) change in pharyngeal transit time.

Secondary

MeasureTime frameDescription
Physiologic change in swallow performance identified on routine Modified barium swallow1 yearPhysiologic changes in swallow performance: oral-motor strength, vocal cord adduction with various food consistencies, presence of penetration/aspiration, length of anterior and superior excursion of larynx, pharyngeal transit time, presence and width of vallecular/piriform residue. Poor anterior or superior excursion of larynx, diminished AP and lateral diameter of UES, presence of residue, penetration/aspiration suggests pharyngeal dysphagia. These measurements will be combined/aggregated to arrive at one reported value.

Countries

United States

Contacts

Primary ContactAssociate Professor of Medicine
ashaker@usc.edu3234422084
Backup ContactAnisa Associate Professor of Medicine
ashaker@usc.edu3234422084

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026